Your browser doesn't support javascript.
loading
Planning for the future of maternal immunization: Building on lessons learned from the COVID-19 pandemic.
Meaney-Delman, Dana; Carroll, Sarah; Polen, Kara; Jatlaoui, Tara C; Meyer, Sarah; Oliver, Sara; Gee, Julianne; Shimabukuro, Tom; Razzaghi, Hilda; Riley, Laura; Galang, Romeo R; Tong, Van; Gilboa, Suzanne; Ellington, Sascha; Cohn, Amanda.
Afiliación
  • Meaney-Delman D; Division of Birth Defects and Infant Disorders, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: vmo0@cdc.gov.
  • Carroll S; American College of Obstetricians and Gynecologists, Washington, D.C, United States.
  • Polen K; Division of Birth Defects and Infant Disorders, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Jatlaoui TC; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Meyer S; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Oliver S; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Gee J; Immunization Safety Office, Division of Healthcare Quality and Promotion, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Shimabukuro T; Immunization Safety Office, Division of Healthcare Quality and Promotion, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Razzaghi H; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Riley L; Department of Obstetrics and Gynecology, Weill Cornell School of Medicine, New York, NY, United States.
  • Galang RR; Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Tong V; Division of Birth Defects and Infant Disorders, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Gilboa S; Division of Birth Defects and Infant Disorders, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Ellington S; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Cohn A; Division of Birth Defects and Infant Disorders, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Vaccine ; 2024 Feb 28.
Article en En | MEDLINE | ID: mdl-38423818
ABSTRACT
As the worldwide COVID-19 pandemic unfolded, the clinical and public health community raced to understand SARS-CoV-2 infection and develop life-saving vaccines. Pregnant persons were disproportionately impacted, experiencing more severe illness and adverse pregnancy outcomes. And yet, when COVID-19 vaccines became available in late 2020, safety and efficacy data were not available to inform their use during pregnancy because pregnant persons were excluded from pre-authorization clinical trials. Concerns about vaccine safety during pregnancy and misinformation linking vaccination and infertility circulated widely, creating a lack of vaccine confidence. Many pregnant people initially chose not to get vaccinated, and while vaccination rates rose after safety and effectiveness data became available, COVID-19 vaccine acceptance was suboptimal and varied across racial and ethnic distribution of the pregnant population. The COVID-19 pandemic experience provided valuable insights that can inform current and future approaches to maternal vaccination against.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Vaccine Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Vaccine Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos